Recent advances in small molecule PROTACs for the treatment of cancer

2020 ◽  
Vol 27 ◽  
Author(s):  
Wen Li ◽  
Reham M. Elhassan ◽  
Xuben Hou ◽  
Hao Fang

: The PROTAC (PROteolysis TArgeting Chimera) technology is a target protein degradation strategy, based on the ubiquitin-proteasome system, which has been gradually developed into a potential means of targeted cancer therapy in recent years. This strategy has already shown significant advantages over traditional small-molecule inhibitors in terms of pharmacodynamics, selectivity, and drug resistance. Several small molecule PROTACs have been in a Phase I clinical trial. Herein, we introduced the mechanism, characteristics, and advantages of PROTAC strategy. And we summarize the recent advances in the development of small-molecule PROTACs for cancer treatment. We hope this review will be helpful in optimizing the design of the ideal small-molecule PROTACs and advancing targeted anticancer research.

2020 ◽  
Vol 12 (10) ◽  
pp. 915-938
Author(s):  
Yichao Wan ◽  
Chunxing Yan ◽  
Han Gao ◽  
Tingting Liu

Proteolysis-targeting chimera (PROTAC) is a new technology to selectively degrade target proteins via ubiquitin-proteasome system. PROTAC molecules (PROTACs) are a class of heterobifunctional molecules, which contain a ligand targeting the protein of interest, a ligand recruiting an E3 ligase and a linker connecting these two ligands. They provide several advantages over traditional inhibitors in potency, selectivity and drug resistance. Thus, many promising PROTACs have been developed in the recent two decades, especially small-molecule PROTACs. In this review, we briefly introduce the mechanism of PROTACs and focus on the progress of small-molecule PROTACs based on different E3 ligases. In addition, we also introduce the opportunities and challenges of small-molecule PROTACs for cancer therapy.


2015 ◽  
Vol 22 (11) ◽  
pp. 1335-1347 ◽  
Author(s):  
Yan Gao ◽  
Jacson Shen ◽  
Lara Milane ◽  
Francis Hornicek ◽  
Mansoor Amiji ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Megan T. Lewno ◽  
Taixing Cui ◽  
Xuejun Wang

Cardiomyocyte death in the form of apoptosis and necrosis represents a major cellular mechanism underlying cardiac pathogenesis. Recent advances in cell death research reveal that not all necrosis is accidental, but rather there are multiple forms of necrosis that are regulated. Necroptosis, the earliest identified regulated necrosis, is perhaps the most studied thus far, and potential links between necroptosis and Cullin-RING ligases (CRLs), the largest family of ubiquitin E3 ligases, have been postulated. Cullin neddylation activates the catalytic dynamic of CRLs; the reverse process, Cullin deneddylation, is performed by the COP9 signalosome holocomplex (CSN) that is formed by eight unique protein subunits, COPS1/CNS1 through COPS8/CNS8. As revealed by cardiomyocyte-restricted knockout of Cops8 (Cops8-cko) in mice, perturbation of Cullin deneddylation in cardiomyocytes impairs not only the functioning of the ubiquitin–proteasome system (UPS) but also the autophagic–lysosomal pathway (ALP). Similar cardiac abnormalities are also observed in Cops6-cko mice; and importantly, loss of the desmosome targeting of COPS6 is recently implicated as a pathogenic factor in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). Cops8-cko causes massive cardiomyocyte death in the form of necrosis rather than apoptosis and rapidly leads to a progressive dilated cardiomyopathy phenotype as well as drastically shortened lifespan in mice. Even a moderate downregulation of Cullin deneddylation as seen in mice with Cops8 hypomorphism exacerbates cardiac proteotoxicity induced by overexpression of misfolded proteins. More recently, it was further demonstrated that cardiomyocyte necrosis caused by Cops8-cko belongs to necroptosis and is mediated by the RIPK1–RIPK3 pathway. This article reviews these recent advances and discusses the potential links between Cullin deneddylation and the necroptotic pathways in hopes of identifying potentially new therapeutic targets for the prevention of cardiomyocyte death.


2019 ◽  
Vol 167 ◽  
pp. 291-311 ◽  
Author(s):  
Aleksandra Golonko ◽  
Tomasz Pienkowski ◽  
Renata Swislocka ◽  
Ryszard Lazny ◽  
Marek Roszko ◽  
...  

2020 ◽  
Vol 8 ◽  
Author(s):  
Hua Jin ◽  
Xiao Lin ◽  
Mengyue Gao ◽  
Liao Cui ◽  
Yun Liu

2018 ◽  
Vol 75 (10) ◽  
pp. 1803-1826 ◽  
Author(s):  
Jin Zhang ◽  
Guan Wang ◽  
Yuxin Zhou ◽  
Yi Chen ◽  
Liang Ouyang ◽  
...  

2011 ◽  
Vol 8 (s1) ◽  
pp. S79-S84
Author(s):  
Lynda Ekou ◽  
Tchirioua Ekou ◽  
Isabelle Opalinski ◽  
Jean Pierre Gesson

The inhibition of HDAC (histone deacetylase) activity by specific inhibitors induces growth arrest, differentiation and apoptosis of transformed or several cancer cells. Some of these inhibitors are in clinical trial at phase I or phase II. The discovery and development of specific HDAC inhibitors are helpful for cancer therapy. In this paper we describe the synthesis of simple inhibitorBhybrid analogue suberoylanilide hydroxamic acid (SAHA), trapoxinB(TPX B) in as little as five steps. This compound is interesting lead for the design of potent inhibitors of histone deacetylase.


2017 ◽  
Vol 22 (4) ◽  
pp. 665-680 ◽  
Author(s):  
Jennifer M. Wickens ◽  
Hashem O. Alsaab ◽  
Prashant Kesharwani ◽  
Ketki Bhise ◽  
Mohd Cairul Iqbal Mohd Amin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document